X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs WOCKHARDT LTD. - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD WOCKHARDT LTD. MERCK LTD/
WOCKHARDT LTD.
 
P/E (TTM) x 47.8 -23.2 - View Chart
P/BV x 7.2 2.4 307.0% View Chart
Dividend Yield % 0.4 0.0 23,885.1%  

Financials

 MERCK LTD   WOCKHARDT LTD.
EQUITY SHARE DATA
    MERCK LTD
Dec-16
WOCKHARDT LTD.
Mar-18
MERCK LTD/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,0601,012 104.7%   
Low Rs623532 117.2%   
Sales per share (Unadj.) Rs632.4355.9 177.7%  
Earnings per share (Unadj.) Rs45.7-60.3 -75.8%  
Cash flow per share (Unadj.) Rs62.3-46.8 -133.3%  
Dividends per share (Unadj.) Rs11.000.01 110,000.0%  
Dividend yield (eoy) %1.30 100,882.4%  
Book value per share (Unadj.) Rs388.8257.8 150.8%  
Shares outstanding (eoy) m16.60110.63 15.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.2 61.4%   
Avg P/E ratio x18.4-12.8 -143.8%  
P/CF ratio (eoy) x13.5-16.5 -81.8%  
Price / Book Value ratio x2.23.0 72.3%  
Dividend payout %24.10 -145,034.5%   
Avg Mkt Cap Rs m13,96985,379 16.4%   
No. of employees `0001.66.3 25.3%   
Total wages/salary Rs m1,4879,371 15.9%   
Avg. sales/employee Rs Th6,631.96,295.0 105.4%   
Avg. wages/employee Rs Th939.21,498.3 62.7%   
Avg. net profit/employee Rs Th479.4-1,066.3 -45.0%   
INCOME DATA
Net Sales Rs m10,49839,369 26.7%  
Other income Rs m2421,202 20.2%   
Total revenues Rs m10,74140,571 26.5%   
Gross profit Rs m1,13518 6,203.8%  
Depreciation Rs m2761,495 18.4%   
Interest Rs m02,555 0.0%   
Profit before tax Rs m1,102-2,830 -39.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m343257 133.6%   
Profit after tax Rs m759-6,669 -11.4%  
Gross profit margin %10.80 23,264.6%  
Effective tax rate %31.1-9.1 -342.9%   
Net profit margin %7.2-16.9 -42.7%  
BALANCE SHEET DATA
Current assets Rs m6,41033,796 19.0%   
Current liabilities Rs m8,82826,917 32.8%   
Net working cap to sales %-23.017.5 -131.9%  
Current ratio x0.71.3 57.8%  
Inventory Days Days5879 72.7%  
Debtors Days Days3889 43.0%  
Net fixed assets Rs m1,40639,664 3.5%   
Share capital Rs m166553 30.0%   
"Free" reserves Rs m6,28627,968 22.5%   
Net worth Rs m6,45528,522 22.6%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m8,82881,620 10.8%  
Interest coverage xNM-0.1-  
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x1.20.5 246.5%   
Return on assets %8.6-5.0 -170.6%  
Return on equity %11.8-23.4 -50.3%  
Return on capital %17.1-7.7 -222.5%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m9599,807 9.8%   
Fx outflow Rs m2,6121,789 146.0%   
Net fx Rs m-1,6538,019 -20.6%   
CASH FLOW
From Operations Rs m1,070684 156.4%  
From Investments Rs m-7506,302 -11.9%  
From Financial Activity Rs m-150-7,695 1.9%  
Net Cashflow Rs m171-664 -25.7%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 2.3 791.3%  
FIIs % 1.0 7.7 13.0%  
ADR/GDR % 0.0 0.1 -  
Free float % 29.1 15.4 189.0%  
Shareholders   28,591 67,757 42.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   SUVEN LIFE  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS